West Pharmaceutical forecasts 2025 results below expectations, shares drop
West Pharmaceutical Services forecast full-year profit and revenue below Wall Street estimates on Thursday due to a strong ...
West Pharma’s stock tanks 33% to lead S&P 500 decliners as guidance misses by a wide margin
West Pharmaceutical Services Inc.’s stock tumbled 33% Thursday, to lead S&P 500 decliners, after the manufacturer of ...
Is WST Stock Undervalued At $200?
Following the earnings announcement, WST stock plummeted 38% due to its disappointing guidance. Over a broader timeframe, its ...
West Pharmaceutical price target lowered to $285 from $355 at BofA
BofA lowered the firm’s price target on West Pharmaceutical (WST) to $285 from $355 and keeps a Buy rating on the shares after the company ...
This Pharma Stock Is Today’s Worst in the S&P 500. Here’s Why.
West Pharmaceutical Services stock sank Thursday after the company issued a full-year outlook that missed analysts’ expectations. Shares plunged 31% to $222.46, putting them on pace for their worst ...
West Pharmaceutical Services 4Q Results Clear Estimates but 2025 Guidance Comes Up Short
For 2025, West Pharmaceutical guided for sales between $2.88 billion and $2.91 billion as well as adjusted earnings per-share in the range of $6 and $6.20. Analysts polled by FactSet expected $3.04 ...
West Pharmaceutical upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank upgraded West Pharmaceutical (WST) to Buy from Hold with a $250 price target Maximize Your Portfolio with Data Driven ...
West Pharmaceutical targets 2-3% organic sales growth for 2025, highlights GLP-1 market expansion
Q4 2024 Management View CEO Eric Green highlighted that the company achieved 3.3% organic revenue growth in Q4 2024, marking a return to quarterly growth. Notable drivers included strong performance ...